Niels Møller

Medical Prognosis Institute A/S engages in the research and development of drugs and treatments for cancer and other related illnesses. It operates through the following segments: X Labs, Predict, Ventures, Personal, and Diagnostic business areas. The X Labs business area offers invent, prototype, and prove relevant techniques, scientific methodologies and business models. The Predict business area utilize the method to generate drug and patient response reports. The Ventures business area focuses on business development ventures. The Personal business area engages in developing business to consumer products and services. The Diagnostic business area operates lung chip diagnostics. The company was founded by Steen Knudsen in September 2004 and is headquartered in Horsholm, Denmark.

Part of Servier SAS, Servier Pharmaceuticals LLC is a privately held pharmaceutical company focused on oncology. The company, based in Boston, MA, was founded in 1954. Servier Pharmaceuticals is committed to innovation and improving the lives of patients, their families, and caregivers. The company invests in research and development to address the unmet needs of patients, particularly in the areas of oncology, cardiovascular diseases, cancers, diabetes, immuno-inflammatory, and neuro-psychiatric diseases. The company offers financial assistance to support patients, advocacy groups, and healthcare professionals. The company strives for transparency in clinical trials and research and development. Servier Pharmaceuticals aims to create a brighter future for all by providing life-saving treatments to a greater number of patients. The company actively seeks alliances, acquisitions, licensing deals, and partnerships to accelerate access to therapies. David K. Lee has been the CEO of the company since 2018.